Clinical trial · Expanded Access
Expanded Access to Navitoclax
NCT03592576CI-TRIAL-00076785no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to navitoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphocytic Leukemia (ALL) | Acute Lymphoblastic Leukemia | ALIAS | 0.85 |
| Lymphoblastic Lymphoma | Lymphoblastic Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Myelofibrosis | Primary Myelofibrosis | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Navitoclax | Drug | — | UNRESOLVED |
| Venetoclax | Drug | Venetoclax | ALIAS |
Eligibility
Eligibility (as posted)
- Minimum age
- 4 Years
Show eligibility record
- sex
- null
- stdAges
- CHILD
- ADULT
- OLDER_ADULT
- criteria
- null
- maximumAge
- null
- minimumAge
- 4 Years
- healthyVolunteers
- false
References
Publications (0)
Data not yet available
No reference posted for this study.